Clinical Trial Update: A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism [Phase 2]

View source ↗

Summary

A Phase 2 randomized open-label study comparing subcutaneous dalteparin to direct oral anticoagulants for cancer-associated venous thromboembolism (VTE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ampulla of Vater Cancer
• Biliary Cancer
• Cancer-associated Thrombosis
• Duodenal Cancer
• Esophageal Cancer
• Esophagogastric Junction Cancer
• Hepatocellular Carcinoma
• Malignant Gastrointestinal Stromal Tumor
• Pancreatic Cancer
• Stomach Cancer

Drugs mentioned

• Dalteparin (subcutaneous) (dalteparin)
• Direct Oral Anticoagulants (DOACs)

Snippet

Sponsor: Asan Medical Center | Conditions: Cancer-associated Thrombosis, Esophageal Cancer | Phase 2 | Status: UNKNOWN